Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis

Yoshito Takeda1
Kazuyuki Tsujino2
Takashi Kijima1
Atsushi Kumanogoh1

1Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; 2Department of Respiratory Medicine, Kinki Central Hospital of the Mutual Aid Association of Public School Teachers, Itami, Hyogo, Japan

Abstract: Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease. Although the precise cause of the disease is still unknown, recent studies have shown that the pathogenesis of pulmonary fibrosis involves multiple mechanisms, with abnormal behavior of alveolar epithelial cells considered a primary event. Pirfenidone is a multifunctional, orally available small molecule with anti-fibrotic, anti-inflammatory, and antioxidative activities, and has been shown to be a modulator of cytokines and growth factors, including TGF-β1, TNF-α, bFGF, IFN-γ, IL-1β, and IL-18 in animal models. Although its precise mechanism of action is not currently clear, pirfenidone is considered to exert inhibitory effects on multiple pathways involved in the pathogenesis of IPF. Two randomized placebo-controlled clinical trials in Japan demonstrated that pirfenidone significantly reduced the rate of decline of vital capacity in IPF patients. A Phase III study showed a significant increase in progression-free survival of patients in pirfenidone-treated groups compared to the placebo group. These results paved the way for the approval of pirfenidone for the treatment of IPF patients in Japan in 2008. The promising results of the Phase II study in Japan led to a larger international Phase III trial (CAPACITY). Subsequently, pirfenidone has also been approved in the European Union, South Korea, and Canada to date. Pirfenidone treatment is generally tolerated. Major adverse events are gastrointestinal symptoms, including decreased appetite, abdominal discomfort and nausea, photosensitivity, and fatigue, but many of these are mild and manageable. Clinical experience has shown that reduction in pirfenidone dose and the supportive use of gastrointestinal drugs are effective ways to manage these symptoms. Thus, pirfenidone treatment provides a means of intervention in the clinical course of IPF, and is a promising candidate for improving patient prognosis. For future development, it is important to establish the appropriate modality of treatment with pirfenidone and/or novel potential drugs.

Keywords: pirfenidone, safety, efficacy, anti-fibrotic drugs

Introduction

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease of unknown etiology. IPF is characterized by progressive deposition of collagen and other extracellular matrix (ECM) molecules.1 Previously, IPF was viewed as a “smoldering” inflammatory response that ultimately led to chronic lung injury with subsequent fibrosis. However, inflammation is no longer regarded as crucial to the etiology of IPF, largely because current anti-inflammatory therapies for IPF have provided little benefit for patients.2 Instead, it has become clear that abnormal behavior of alveolar epithelial cells (AECs) is the primary event in the development of pulmonary fibrosis.3,4 The disease process is initiated through repetitive injury of AECs, causing AEC activation, which in turn leads to the recruitment of immune cells and fibroblasts within
the lung microenvironment. Aberrantly activated AECs, in cooperation with migrated immune cells and fibroblasts, secrete and activate latent TGF-β1, as well as other pro-fibrotic factors, which promote the differentiation of fibroblasts and AECs to myofibroblasts, resulting in overproduction of ECM in the lung. Epithelial–mesenchymal transition (EMT) may also be a source of ECM-producing (myo)fibroblasts in IPF.

Accumulating evidence suggests that both intrinsic factors in host lungs (ie, genetic predisposition), and extrinsic factors that accelerate injury of AECs play an etiologic role in IPF. Genetic predisposition is evidenced by the association of genes with disease, including telomerase reverse transcriptase (TERT) and MUC5B. Close attention has also been paid to β1 integrins in AECs and fibroblasts, focusing on their potential roles in pulmonary fibrosis. Integrin-related tetraspanin CD151 is essential for AECs to maintain epithelial integrity via firm adhesion to the basement membrane. The deletion of CD151 promotes mesenchymal-like changes and activation of TGF-β signaling in AECs in mice, and downregulation of CD151 in AECs of IPF patients is considered to be the result of an extrinsic factor, rather than a genetic factor.

Until pirfenidone was approved in 2008, no drug was proven to be effective to treat IPF, although several clinical trials of potential agents have been conducted. Novel treatments for IPF, including bosentan (dual endothelin receptor antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiesterase type-5 inhibitor), etanercept (antibody antagonist), imatinib (tyrosine kinase inhibitor), sildenafil (phosphodiestera...
of TNF-α production. Pirfenidone inhibited TNF-α production by post-transcriptional regulation of the TNF-α gene. Pirfenidone also enhanced the production of IL-10 in this model. These effects on TNF-α and IL-10 are also considered to be involved in the anti-fibrotic activities of pirfenidone.

Oku et al investigated the anti-fibrotic effect of pirfenidone in bleomycin-induced lung fibrosis in mice using prednisolone as a reference agent. Mice were injected intravenously (iv) with bleomycin (10 mg/kg) for 5 consecutive days. In this model, lung inflammation occurred and peaked on day 10 after the first injection of bleomycin. Following inflammation, lung fibrosis was initiated and progressed gradually. Both pirfenidone and prednisolone suppressed lung inflammation in this model, but only pirfenidone significantly suppressed the subsequent lung fibrosis as evaluated by hydroxyproline content and histological fibrotic score. Pirfenidone suppressed the elevation of fibrogenic factors such as transforming growth factor (TGF)-β1 and basic fibroblast growth factor (bFGF). Furthermore, pirfenidone prevented the lowering of IFN-γ, which is known to be an anti-fibrotic cytokine through inhibition of TGF-β1 production and is also involved in type 1 helper T cell/type 2 helper T cell (Th1/Th2) balance. Prednisolone, however, did not suppress the changes in these factors. On the other hand, proinflammatory cytokines in the lungs, such as IL-1β, IL-6, and monocyte chemoattractant protein (MCP)-1 were suppressed by both agents. In addition, it was reported that pirfenidone inhibited platelet-derived growth factor (PDGF) production in bleomycin-induced lung fibrosis in hamsters.

The anti-fibrotic activity of pirfenidone is mainly considered to be due to the suppression of TGF-β. TGF-β is one of the most studied pro-fibrotic cytokines. In the lung, TGF-β is produced by a wide variety of cell types, including alveolar macrophages, neutrophils, activated alveolar epithelial cells, endothelial cells, fibroblasts, and myofibroblasts. TGF-β induces the proliferation of macrophages and fibroblasts via PDGF expression. In these cells, TGF-β also stimulates the expression of a number of other proinflammatory and fibrogenic cytokines, such as TNF-α, IL-1β, and IL-13, thereby further enhancing and perpetuating the fibrotic response.

A recent report implied that pirfenidone suppressed the formation of a multi-molecular complex known as the NLRP3 (NOD-like receptor pyrin domain containing 3) inflammasome. This led to attenuation of the expression of IL-1β, which induces inflammatory and pro-fibrotic responses. That study also reported that pirfenidone reduced left ventricular remodeling and subsequent fibrosis in a mouse model of cardiac fibrosis induced by thoracic aortic constriction (TAC). TAC induced an elevation in inflammatory cell infiltration, and the production of ROS and inflammatory mediators including c-Jun, NLRP3, and IL-1β, but pirfenidone attenuated these effects. The upregulation of NLRP3 following TAC suggests that inflammasome...
Efficacy

Clinical trials of pirfenidone for IPF

Two open-label trials and four double-blind trials have been carried out with pirfenidone for IPF.\(^28-42\) The first double-blind trial was a Phase II study in Japan.\(^40\) This study was stopped early (at 9 months) due to an increased incidence of acute exacerbations in patients treated with placebo, while none occurred in the pirfenidone group. The primary endpoint (lowest saturation of peripheral oxygen [SpO\(_2\)] under exertion) was not significantly different between patients treated with pirfenidone (1,800 mg/day) and patients treated with placebo at 9 months, but a significant reduction in the decline in vital capacity (VC) was shown in the pirfenidone group, suggesting potential efficacy for IPF patients.

A Phase III clinical trial of pirfenidone has also been conducted in Japan.\(^41\) The trial included 275 patients with IPF (20–75 years of age). Inclusion criteria were based on: 1) oxygen desaturation of ≥5% difference between resting SpO\(_2\) and the lowest SpO\(_2\) during a 6-minute steady-state exercise test (6MET), and 2) a lowest SpO\(_2\) during the 6MET of ≥85% while breathing air. Patients were randomized to three groups; high dose (1,800 mg/day), low dose (1,200 mg/day), and placebo, at a ratio of 2:1:2 for a period of 52 weeks. The primary endpoint was the change in VC from baseline at 52 weeks. This study demonstrated that the decline in VC was significantly smaller (P<0.0416) in the high-dose pirfenidone group (−0.09 L) than in the placebo group (−0.16 L). The absolute difference in VC was 70 mL and the relative difference was 44%. The decline in VC in the low-dose pirfenidone group (−0.08 L) was also significantly reduced (P=0.0394) compared to that in the placebo group (3). This study also showed that pirfenidone significantly (P=0.0280) increased progression-free survival (PFS) (Figure 4). PFS was defined as the time until death and/or ≥10% decline in VC from baseline. Other secondary endpoints (SpO\(_2\), serum markers), however, did not reach statistical significance among the groups.

Two international clinical trials (CAPACITY [Clinical Studies Assessing Pirfenidone in idiopathic pulmonary fibrosis: Research of Efficacy and Safety Outcomes]-1, -2) were conducted in North America, Australia, and Europe.\(^42\) The decline in percentage predicted forced vital capacity (FVC) at 72 weeks was significantly reduced in pirfenidone-treated (2,400 mg/day) patients compared to those treated with placebo in CAPACITY-2, while the difference in FVC change at 72 weeks was not significant in CAPACITY-1. Pooled analysis of the two trials showed that pirfenidone significantly improved 6-minute walking distance.\(^43\) Applications for the approval of pirfenidone were submitted with the results of the CAPACITY trials to the European and US authorities. The data from the CAPACITY trials were assessed together with the data from the Japanese Phase III study by the European Medicines Agency (EMA), and pirfenidone was approved in the EU in March 2011. However, the US Food and Drug Administration (FDA) requested an additional trial, and that trial, the ASCEND (Assessment of Pirfenidone to Confirm Efficacy and Safety in IPF) study, is currently in progress. The enrollment of IPF patients (555 patients) was completed in January 2013, and top-line results
from the study are expected to be available in the second quarter of 2014.

**Meta-analysis (Cochrane review)**

A recent Cochrane review summarized the studies of ten non-steroid agents for the treatment of IPF and identified IFN-\(\gamma\)-1b and pirfenidone as suitable for analysis.\(^4\) The meta-analysis combining the data from two IFN-\(\gamma\)-1b randomized controlled trials showed no significant difference between IFN-\(\gamma\)-1b and placebo in the clinical endpoint of overall survival (Figure 5A). Since meta-analysis of three Phase III studies of pirfenidone showed an increase in PFS (Figure 5B) and a suppression of decline in VC, pirfenidone is the only drug to show a significant effect on IPF to date.

Among prognostic factors for IPF, a decline in VC of 10% or more within 12 months is considered to be of most prognostic value.\(^45\) Marginal decline (\(\geq 5\%\)) in VC was also reported to be associated with poor prognosis in IPF.\(^46\) Recently, there have been active debates on the most clinically meaningful endpoint for clinical trials of therapeutic agents for IPF.\(^47\)–\(^49\) Although it has been proposed that all-cause mortality and all-cause hospitalization are the most appropriate endpoints,\(^47\) there are some limitations that should be considered.\(^48\) For clinical trials to be adequate for evaluation of mortality as an endpoint, in terms of statistical power, they need to include a high number of patients (>2,500) and require a much longer follow-up time (>3 years).\(^50\) In addition, patients will not agree to stay in a trial for a long period of time, in either the placebo or the treatment arm, if their disease progresses. For these reasons, a surrogate marker for mortality is needed and serial changes in VC or FVC are currently considered to be the preferred option. It has also been proposed that PFS could be a clinically meaningful endpoint.\(^51\)

**Sub-analysis of the Phase III clinical trial in Japan**

Sub-analyses of the Japanese Phase III trial of pirfenidone have been carried out. Azuma et al reported that patients with a percentage predicted VC \(\geq 70\%\), and a SpO\(_2\) at exertion \(< 90\%\) at baseline most likely benefited from pirfenidone.\(^52\) In such patients, pirfenidone significantly suppressed the worsening of subjective symptoms of cough and dyspnea as compared to placebo. Furthermore, Taniguchi et al showed that 70% of patients who had not worsened by 3 months, using a threshold of 5% change in VC, continued not to worsen by 12 months after beginning pirfenidone treatment.\(^53\) This finding suggests that VC changes (\(\geq 5\%\)) at 3 months may be indicative for making clinical decisions on the continuation of pirfenidone treatment.

According to an exploratory analysis of the Japanese Phase III trial, pirfenidone appears to be more efficacious in the early stage than in the advanced stage of IPF.\(^52\) Therefore, an early and accurate diagnosis of IPF is critical for ensuring early intervention with pirfenidone, in order to suppress IPF progression at the early stage. With early intervention, improvements in the long-term clinical outcome of this
devastating disease might be anticipated. Recently, Cottin and Cordier pointed out the value of “Velcro crackles” for early diagnosis, although the assessment of Velcro-like crackling sounds upon lung auscultation is already routinely used for the diagnosis in Japan. There are several parameters which are informative in determining when or whether to initiate treatment, including subjective symptoms, desaturation of oxygen, and decline in VC (>5%) within 3–6 months. However, with respect to early treatment, it must be taken into account that IPF is a heterogeneous disease, and that while many patients progress, some do not. Heterogeneous components of the disease may affect the response to treatment with pirfenidone, although factors which predict the response to pirfenidone have not yet been elucidated.

**Figure 4** Pirfenidone increased PFS in 1,800 mg/day and 1,200 mg/day pirfenidone groups as compared to the placebo group in a Phase III study of IPF patients in Japan.  
**Abbreviations:** IPF, idiopathic pulmonary fibrosis; PFS, progression-free survival.

**Figure 5** Forest plot of pirfenidone (A) or interferon-γ-1b (B) versus placebo in improving PFS in IPF.  
**Notes:** Reproduced from Spagnolo et al. Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.  
**Abbreviations:** CI, confidence interval; HR, hazard ratio; IPF, idiopathic pulmonary fibrosis; PFS, progression-free survival.
Phase II and Phase III clinical trials in Japan showed that pirfenidone was relatively well tolerated in patients with IPF. Major adverse events in the pooled pirfenidone groups from these two trials were photosensitivity reaction (51.7%), decreased appetite (23.0%), abdominal discomfort (14.0%), and nausea (12.1%). In the laboratory tests, elevation of γ-GTP was reported in 20.0% of patients receiving pirfenidone. Adverse events with an incidence ≥5% are listed in Table 1. International multi-center Phase III trials (CAPACITY) also showed that pirfenidone was well tolerated for IPF patients. The type and frequency of adverse events were generally consistent with those in Japanese clinical trials. There have been no reports on any ethnic differences in the pharmacology of pirfenidone.

The photosensitivity reaction was generally mild-to-moderate in severity, and only in 3% (n=5) of patients in pirfenidone groups (n=164) did these result in treatment discontinuation in the Phase III trial in Japan. Photosensitivity reactions are minimized by adequate UV protection, including avoiding exposure to direct sunlight and use of protective sunscreens. Recently, Okuda et al reported the safety profile of pirfenidone in 76 patients with IPF in clinical practice. The most frequent adverse event was anorexia (decreased appetite) with an incidence of 42.1%, although the grade of anorexia in most patients was mild (two patients with grade 3 and others with grade 1 or 2) (Table 2). They reported that anorexia improved in 84% of affected patients following reduction of the pirfenidone dose. On the other hand, the incidence of photosensitivity reaction in clinical practice was 18.4%, which was lower than that reported in Phase II and III clinical trials in Japan. The incidences of other adverse events in clinical practice were similar to those in clinical trials in Japan.

Findings from clinical trials and clinical practice indicate that one of the most important issues for the continuation of pirfenidone therapy is the management of gastrointestinal symptoms, including decreased appetite, abdominal discomfort, and nausea, in order to gain maximal benefit from pirfenidone.

It might be an important factor for safety that pirfenidone has little suppressive effect on humoral and cellular immunity. Increased susceptibility to infection is anticipated to be less of a concern with clinical use of pirfenidone than with corticosteroids, and indeed this is considered to be one of the benefits of pirfenidone.

Routine toxicity screening performed during preclinical development showed that pirfenidone induced photogenotoxicity in an in vitro assay using Chinese hamster ovary (CHO) cells. Because the concentration of pirfenidone required for photogenotoxicity was near the upper limit estimated from pharmacokinetics in healthy humans, a warning for an increased risk of skin cancer is described in the package insert supplied with pirfenidone in Japan. There have been no reports of skin cancer determined to be caused by pirfenidone since its launch in Japan, nor in the RECAP trial (CAPACITY extension study) or during subsequent clinical use of pirfenidone in the EU. Increased risk of skin cancer is described in the package insert for pirfenidone in the EU. Therefore, although the observation period and the number of cases treated are still limited, the increase in risk of the development of skin cancer when using pirfenidone is considered to be very low.

### Current clinical status of pirfenidone for IPF

As of September 2013, in addition to Japan, pirfenidone has been approved for the treatment of IPF in the European Union, Canada, Russia, and the United States.
Summary and future directions

Pirfenidone has been used for the treatment of IPF in Japan for more than 5 years, and it is now also available for IPF patients in several countries in the EU, in South Korea, and in Canada. A PMS in Japan and clinical experiences in "real world" settings have demonstrated the benefit/risk profile of pirfenidone for the treatment of IPF. The profiles of adverse events in clinical practice were generally consistent with those in clinical trials, and serious adverse events were rare. In a 2011 statement from ATS/ERS/JRS/ALAT, pirfenidone received a "weak no" (ie, against the use of these treatments for most patients) recommendation. However, randomized controlled trial data published since that time indicate that reassessment of the treatment guidelines for IPF may be warranted. Combination treatment with prednisone, azathioprine, and NAC, as well as treatment with warfarin, was given a "weak no" recommendation; however, this should be reassessed given the safety concerns brought to light by the PANTHER-IPF trial. The "weak no" recommendation for the use of pirfenidone should also be reevaluated given the promising findings from the three Phase III trials mentioned earlier. Recently, recommendation for the use of pirfenidone was reassessed in several European countries. In German guidelines published early in 2013, pirfenidone received a "weak yes" for the treatment of IPF patients with mild-to-moderate severity. Spanish guidelines were also published in August 2013 and pirfenidone is recommended as a first-line treatment for mild-to-moderate IPF patients.

More effective therapy would ensure that the benefits for patients with IPF are maximized. Approaches to increasing therapeutic efficacy might include the selection of patients positive for markers which are predictive of drug response, or combination drug treatment with pirfenidone and NAC or other promising new drugs, or even with corticosteroids and/or immunosuppressants for patients with severe disease or with inflammatory components. BIBF 1120 (nintedanib) is a kinase inhibitor originally developed as an agent for cancer treatment, which simultaneously inhibits three receptor families implicated in angiogenesis: PDGF, vascular endothelial growth factor (VEGF), and FGF. A Phase II 12-month, randomized and placebo-controlled study of BIBF 1120 (TOMORROW [To Improve Pulmonary Fibrosis With BIBF1120]) study was conducted to evaluate its safety and efficacy in IPF. Although this study did not reach significance for its primary endpoint (decline of VC over a 12-month period, tested by closed testing procedure), the annual rate of decline in FVC in the group receiving 300 mg/day of BIBF 1120 was 0.06 L, as compared with 0.19 L in the placebo group.
group. Moderate gastrointestinal symptoms and liver toxicity were reported in the high-dose (300 mg/day BIBF 1120) arm compared with placebo. Currently, two multinational Phase III studies of BIBF 1120 are being carried out to determine its efficacy and safety for the treatment of IPF.

In terms of the future development of IPF treatment, establishing the appropriate modality of treatment with pirfenidone and/or new potential novel drugs will contribute to the effective treatment of IPF patients.

Acknowledgments

We thank Dr Hisashi Oku and Dr Shuichiro Inagaki (Shionogi & Co, Ltd) for helpful discussions and critical reading of the manuscript.

Disclosure

The authors report no conflicts of interest in this work.

References


